Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Finerenone Pediatric ODT vs Adult Tablet
NCT02956109Phase 1Completed
- Sponsor
- Bayer
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of finerenone in chronic kidney disease (CKD) (4 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration vs. Time Curve at 24 hours, Maximum Plasma Concentration at 24 hours and 1 more. Started Nov 2016; status: completed.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02956109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956109.